NeuroPace (NASDAQ:NPCE) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

NeuroPace (NASDAQ:NPCE) had its target price raised by equities research analysts at JPMorgan Chase & Co. from $16.00 to $18.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price would suggest a potential upside of 39.37% from the stock’s current price.

Several other research firms have also recently weighed in on NPCE. Cantor Fitzgerald restated an “overweight” rating and set a $16.00 price objective on shares of NeuroPace in a research report on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of NeuroPace in a research report on Wednesday, October 8th. Leerink Partners reiterated an “outperform” rating and issued a $19.00 target price on shares of NeuroPace in a research report on Wednesday. Wells Fargo & Company lifted their target price on shares of NeuroPace from $15.00 to $16.00 and gave the stock an “overweight” rating in a research report on Wednesday. Finally, Zacks Research lowered shares of NeuroPace from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 13th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $17.33.

NeuroPace Stock Performance

NPCE traded up $3.52 on Wednesday, hitting $12.92. The company’s stock had a trading volume of 1,144,208 shares, compared to its average volume of 250,898. The company’s 50 day simple moving average is $10.13 and its 200-day simple moving average is $10.83. The firm has a market cap of $427.24 million, a P/E ratio of -15.38 and a beta of 1.90. NeuroPace has a 12 month low of $6.63 and a 12 month high of $18.98. The company has a quick ratio of 4.51, a current ratio of 5.47 and a debt-to-equity ratio of 3.02.

NeuroPace (NASDAQ:NPCE) last posted its earnings results on Tuesday, November 4th. The company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.09. NeuroPace had a negative net margin of 29.29% and a negative return on equity of 168.61%. The business had revenue of $27.35 million for the quarter, compared to analysts’ expectations of $24.64 million. NeuroPace has set its FY 2025 guidance at EPS. Analysts forecast that NeuroPace will post -1 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in the stock. First Light Asset Management LLC purchased a new position in shares of NeuroPace during the first quarter valued at approximately $19,468,000. Armistice Capital LLC raised its holdings in shares of NeuroPace by 94.7% during the first quarter. Armistice Capital LLC now owns 1,153,614 shares of the company’s stock valued at $14,178,000 after purchasing an additional 561,000 shares during the last quarter. Deutsche Bank AG raised its holdings in shares of NeuroPace by 124.0% during the first quarter. Deutsche Bank AG now owns 924,274 shares of the company’s stock valued at $11,359,000 after purchasing an additional 511,662 shares during the last quarter. Driehaus Capital Management LLC purchased a new position in shares of NeuroPace during the first quarter valued at approximately $9,874,000. Finally, Geode Capital Management LLC raised its holdings in shares of NeuroPace by 44.6% during the second quarter. Geode Capital Management LLC now owns 485,162 shares of the company’s stock valued at $5,406,000 after purchasing an additional 149,595 shares during the last quarter. 78.83% of the stock is owned by hedge funds and other institutional investors.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.